SITC Archive Library

The International Society for Biological Therapy of Cancer (iSBTC) 24^th Annual Meeting: iSBTc-FDA-NCI Workshop on Prognostic and Predictive Immunologic Biomarkers in Cancer
October 28, 2009
Gaylord National Hotel in National Harbor in Washington, D.C.

Program Organizers
Lisa H. Butterfield, PhD - University of Pittsburgh
Mary L. Disis, MD -  University of Washington
Samir Khleif, MD - National Cancer Institute, CCRM
Francesco Marincola, MD - National Institutes of Health, DTM
Magdalena Thurin, PhD - National Cancer Institute, NIH - Diagnostic Research

Program Summary
The iSBTc-FDA Task Force on Immunotherapy Biomarkers has worked do identify best practices of standardized and validated immune monitoring procedures and assays to promote inter-trial comparisons and identify strategies for the identification of novel biomarkers that may enhance our understanding of principles of governing human cancer immune biology and, consequently, implement their clinical application. The results of these efforts and the developed best practices will be presented and discussed during this Workshop and in resulting post-meeting documents.

Presentations and video recordings are available based on permission from presenters.